Discloses the use of tolerogenic T cells in the manufacture of a composition to reduce transplant rejection in a transplant patient or for inducing immune tolerance to an antigen in a subject in need thereof. Further discloses methods to generate tolerogenic T cells. The tolerogenic T cells are the product of a method whereby: (i) previously isolated T cells or suppressor T cells are contacted with an amount of non-depleting anti-CD8 antibody during the T cell priming phase (ii) the priming phase is carried out with addition of an antigen and with isolated dendritic cells obtained from monocytes cultured with GM-CSF and IFN-alpha-2b (iii) wherein the T cell priming is effective to induce a tolerogenic T cell or suppressor T cell.
